Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies with mice. The new antibody works by targeting the voltage-sensitive sodium ...

During the pandemic, physicians used infusions of monoclonal antibodies to help patients fight off COVID-19 infections. Now, in response to the U.S. opioid crisis, ... NaV1.7, NaV1.8 and NaV1.9.

A multi-platform antibody discovery approach (phage display, llama immunization) has enabled TetraGenetics to identify functional anti-Nav1.8 antibodies that selectively inhibit Nav1.8 currents in ...

Siteone Therapeutics Inc. has provided details on the discovery of highly selective, potent, state-independent inhibitors of Nav1.7, a nonopioid target for the potential treatment of pain. While prior ...

But now, with recent advances in genomic engineering, targeting Nav1.7 as a potential therapeutic avenue for the treatment of neuropathic pain is a new approach that may address these challenges.

In the new study, the researchers deleted Nav1.7 genes from these collagen-producing cells and significantly reduced joint damage in two osteoarthritis models in mice. They also demonstrated that ...

Beginning with Nav1.7-associated small fiber neuralgia, ... Development of a Competitive Ligand-Binding Assay to Detect Neutralizing Antibodies Against Chimeric Antigen Receptor of Regulatory T Cells ...

Efforts at Abbvie Inc. to selectively target voltage-gated sodium channel subunit alpha Nav1.7 to treat pain led to the discovery of quinoline and quinolone agents and, through structure-activity ...

For those reasons, innovation in the field was highly needed. Voltage-gated sodium channels [NaV], notably NaV1.7, 1.8 and 1.9, play a key role in the transmission of pain in the nervous system.

With Rosetta, the researchers are designing complex virtual models of proteins and analyzing which ones might best fit the NaV1.7, NaV1.8 and NaV1.9 nerve channels.